Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01690884 · ClinicalTrials.gov registry record · Phase 1
Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake
A Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01690884 is a Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 28 participants.
The verdict
NCT01690884, a Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The investigators are trying to determine if a single dose of Ticagrelor will increase delivery of intraarterially-infused adenosine into the forearm interstitium, consistent with adenosine reuptake blockade.
Interventions
- DRUG Adenosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2012-08 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01690884
The ClinicalTrials.gov registry entry for NCT01690884 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adenosine is the first listed.
NCT01690884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01690884 about?
NCT01690884 is a clinical study titled "Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake". The investigators are trying to determine if a single dose of Ticagrelor will increase delivery of intraarterially-infused adenosine into the forearm interstitium, consistent with adenosine reuptake blockade.
What is the current status of trial NCT01690884?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2012-08. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01690884?
The interventions under investigation include: Adenosine (DRUG).
Who is sponsoring clinical trial NCT01690884?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.